Crossmark

Efficacy and safety of rifaximin associated with standard triple therapy (omeprazole, clarithromycin and amoxicillin) for H. pylori eradication: A phase IV pilot clinical trial

Crossref DOI link: https://doi.org/10.1016/j.gastre.2017.05.010

Published Print: 2017-12

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Ramas, Mercedes

Donday, Maria G.

McNicholl, Adrian G.

Gisbert, Javier P.
License Information

Text and Data Mining valid from 2017-12-01
More Information

This article is maintained by: Elsevier

Article Title: Efficacy and safety of rifaximin associated with standard triple therapy (omeprazole, clarithromycin and amoxicillin) for H. pylori eradication: A phase IV pilot clinical trial

Journal Title: Gastroenterología y Hepatología (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.gastre.2017.05.010

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.gastrohep.2017.05.017

Content Type: article

Copyright: © 2017 Elsevier España, S.L.U. All rights reserved.

Document is current

Any future updates will be listed below